Key takeaways
- GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. GHK was first isolated from human plasma in 1973.
- Most research is in cell cultures and animals. The small human skin studies are known mainly through a 2018 review by GHK’s discoverer.
- The human studies applied it to the skin; most were conference posters or pilot reports. The one PubMed-indexed randomised trial of a skin-care regimen found no objective difference from the comparison routine.
- We found no controlled trial of injected GHK-Cu, published or registered. FDA says there are limited human data on injectable GHK-Cu.
- No medicine containing it appears in Drugs@FDA. As a cosmetic ingredient it needs no FDA approval; FDA says a product’s status “is determined by a product’s intended use”.
01What is GHK-Cu?
GHK-Cu is a three-amino-acid peptide, GHK (glycine–histidine–lysine), bound to copper(II). GHK has a high affinity for copper(II). It was first isolated in 1973 as a factor in human plasma that changed protein synthesis in liver tissue.
Plasma levels of GHK are reported to decline with age, one reason it attracted interest in aging-skin research.
02Has GHK-Cu been studied in humans?
The controlled human studies applied it to the skin. We found no controlled trial of injected GHK-Cu, published or registered (PubMed and ClinicalTrials.gov, 18 Nov 2026).
Sources: Pickart & Margolina, Int J Mol Sci, 2018; registry and PubMed searches, 18 Nov 2026
03What have GHK-Cu studies measured?
Mostly cell and animal studies, plus small skin studies in people. Cell and animal findings are not evidence of an effect in people.
Stimulation of collagen, elastin and glycosaminoglycan synthesis in fibroblast cultures.
Connectivity-map analyses suggest GHK shifts expression of many genes; these are computational, not clinical, findings.
Small studies of creams, mostly 12 weeks long, measured skin density, thickness and wrinkles; most were conference posters known through a 2018 review by GHK’s discoverer. The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing (13 completers), found no objective difference from the comparison routine.
04How strong is the evidence on GHK-Cu?
| Area studied | Main evidence | Human data | Grade |
|---|---|---|---|
| Skin appearance (topical) | Cell and animal studies | Small studies, mostly conference posters; one indexed randomised trial with no objective difference | Early human |
| Any route other than the skin | Animal studies | No controlled trial found | Preclinical |
05What hasn't GHK-Cu research shown?
- That findings on skin apply to any other route. We found no controlled trial of GHK-Cu given any other way.
- Large, independent, randomised trials of any route.
- Long-term safety in people. For injectable GHK-Cu, FDA says “there are limited data in humans to inform safety-related considerations”.
06Is GHK-Cu an approved medicine? Status, Nov 2026
No medicine containing GHK-Cu appears in Drugs@FDA. Its status as a cosmetic ingredient and on FDA’s compounding page is set out below.
- CosmeticsCosmetic ingredient
Listed in cosmetics as copper tripeptide-1. FDA says cosmetic ingredients, apart from colour additives, need no approval before sale, and that whether a product is a cosmetic or a drug “is determined by a product’s intended use”.
- FDA listCategory 2 nomination withdrawn
FDA’s compounding page (content current 22 April 2026) lists GHK-Cu, for injectable routes, among substances previously in Category 2, the category for bulk substances that may present significant safety risks, whose nominations were withdrawn by the nominators. FDA’s note cites possible immune reactions from aggregation and peptide-related impurities.
- May 2026Category 1, except injection
FDA’s list of nominated bulk substances (updated 14 May 2026) places GHK-Cu, except for injectable routes, in Category 1, “bulk drug substances under evaluation”. FDA had removed it on 22 April when the nominations were withdrawn; one nominator then said it had meant to withdraw only the injectable route.
- Jul–Oct 2026Not in the 2026 reviews
GHK-Cu was not among the peptides on the agenda of FDA’s advisory committee in July 2026, or in HHS’s October 2026 enforcement-discretion policy. FDA says the committee will discuss GHK-Cu at a meeting before the end of February 2027.
- NowNo approved medicine
No medicine containing it appears in Drugs@FDA.
07Sources
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int, 2015:648108. pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 2018;19(7):1987. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 18 Nov 2026. www.fda.gov/media/94155/download
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027; agenda includes GHK-Cu). Advisory committee page, published 15 Apr 2026; read 18 Nov 2026. www.fda.gov/advisory-committees/pharmacy-compounding-advis…
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-…
- U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Web page, content current as of 11 Sep 2024; read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmeti…
- PubChem. Prezatide copper, CID 71587328: synonyms include copper tripeptide-1 and GHK copper. Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328
- ClinicalTrials.gov. Search results for “GHK-Cu” and “copper tripeptide-1”; PubMed search for controlled trials of injected GHK-Cu: none found. Registry and database searches, 18 Nov 2026. clinicaltrials.gov/search?term=GHK-Cu
- U.S. Food and Drug Administration. Drugs@FDA data, queried through the openFDA API for active ingredients “prezatide”, “copper tripeptide” and “GHK”: no matches. Database query, 18 Nov 2026. api.fda.gov/drug/drugsfda.json?search=products.active_ingre…
- FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current 6 Aug 2026. www.fda.gov/advisory-committees/advisory-committee-calendar…
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcemen…